{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:09:50Z","timestamp":1792026590294,"version":"4.4.0"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T00:00:00Z","timestamp":1699142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Biologics targeting IL\u201023 and IL\u201017 show efficacy and safety in the treatment of moderate\u2010to\u2010severe psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate drug survival in patients with psoriasis treated with biologics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>We performed a comparative evaluation of the achievement of PASI\u00a090 and PASI \u2264 3 at 16, 28, and 52\u00a0weeks along with a DS (drug survival) analysis with IL\u201017 and IL\u201023 inhibitors brodalumab, ixekizumab, secukinumab, risankizumab, tildrakizumab, and guselkumab on 1,057 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>IL\u201017 inhibitors showed a faster achievement of PASI\u00a090 and PASI \u2264\u00a03 with significant superiority over IL\u201023 inhibitors at week 16 (p\u00a0&lt;\u00a00.001; 56% vs. 42% and 70% vs. 59%, respectively). A difference was shown in favor of IL\u201023 inhibitors regarding DS (p\u00a0&lt;\u00a00.001), which was 88% at 24 months vs. 75% for IL\u201017 inhibitors. In multivariate analysis, IL\u201023 inhibitors (HR 0.54 CI 0.37\u20130.78, p\u00a0=\u00a00.001), and male sex (HR 0.57 CI 0.42\u20130.76, p\u00a0&lt;\u00a00.001) were all associated with a lower probability of drug interruption. Risankizumab (HR 0.42 CI 0.26\u20100.69, p\u00a0=\u00a00.001), guselkumab (HR 0.49 CI 0.24\u20130.99, p\u00a0=\u00a00.046), and male sex (HR 0.57 CI 0.43\u20130.77, p\u00a0&lt;\u00a00.001) were associated with a lower probability of drug interruption than secukinumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>IL\u201023 inhibitors showed the best performance on DS. Overall, the most effective class was IL\u201017 inhibitors considering the short\u2010term effectiveness, but long\u2010term effectiveness is in favor of anti\u2010IL\u201023.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ddg.15251","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T04:04:47Z","timestamp":1699243487000},"page":"34-42","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-3219","authenticated-orcid":false,"given":"Luca","family":"Mastorino","sequence":"first","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Susca","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Cariti","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Siliquini","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Verrone","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Stroppiana","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18069"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21048"},{"issue":"9","key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/ddg.14832","article-title":"Biologics for pediatric moderate\u2010to\u2010severe plaque psoriasis: a systematic review and network meta\u2010analysis","volume":"20","author":"Huang IH","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ddg.14377","article-title":"Considerations for patients with psoriasis travelling under immunosuppression","volume":"19","author":"Stephan B","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/ddg.15071","article-title":"Cardiovascular comorbidity in psoriasis \u2010 psoriatic inflammation is more than just skin deep","volume":"21","author":"Kommoss KS","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1970706"},{"issue":"5","key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/ddg.14789","article-title":"Therapy of psoriasis during pregnancy and breast\u2010feeding","volume":"20","author":"Balakirski G","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15033"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00475-8"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19135"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217372"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0793"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18851"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30952-3"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19325"},{"issue":"5","key":"e_1_2_7_18_1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"5","author":"Sbidian E","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00598-4"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15146"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00722-y"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1961998"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-18790-9"},{"key":"e_1_2_7_25_1","article-title":"Drug survival and efficacy of anti\u2010interleukin 23 biologics in psoriasis: a comparative study on different agents. [published online ahead of print, 2022 Nov 29]","author":"Roccuzzo G","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2082354"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2081655"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.2909"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42010"},{"issue":"3","key":"e_1_2_7_30_1","first-page":"247","article-title":"Onset of action of biologics in patients with moderate\u2010to\u2010severe psoriasis","volume":"17","author":"Papp KA","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.026"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14874"},{"issue":"7","key":"e_1_2_7_33_1","first-page":"675","article-title":"Cytokines of the IL\u201017 family in psoriasis","volume":"18","author":"Lauffer F","year":"2020","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T05:25:50Z","timestamp":1705901150000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.15251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,5]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/ddg.15251"],"URL":"https:\/\/doi.org\/10.1111\/ddg.15251","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,5]]},"assertion":[{"value":"2023-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}